These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35918873)

  • 41. Understanding pharmaceutical quality by design.
    Yu LX; Amidon G; Khan MA; Hoag SW; Polli J; Raju GK; Woodcock J
    AAPS J; 2014 Jul; 16(4):771-83. PubMed ID: 24854893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Harnessing artificial intelligence for the next generation of 3D printed medicines.
    Elbadawi M; McCoubrey LE; Gavins FKH; Ong JJ; Goyanes A; Gaisford S; Basit AW
    Adv Drug Deliv Rev; 2021 Aug; 175():113805. PubMed ID: 34019957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Study on the Application and Use of Artificial Intelligence to Support Drug Development.
    Lamberti MJ; Wilkinson M; Donzanti BA; Wohlhieter GE; Parikh S; Wilkins RG; Getz K
    Clin Ther; 2019 Aug; 41(8):1414-1426. PubMed ID: 31248680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toward biotherapeutic product real-time quality monitoring.
    Guerra A; von Stosch M; Glassey J
    Crit Rev Biotechnol; 2019 May; 39(3):289-305. PubMed ID: 30724608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recommendations for Enhancing Quality and Capability of Indian Biopharmaceutical Industry: Summary of a Workshop.
    Uppal A; Koduri CK; Yadlapalli S; Chirmule N; Chakrabarti R; Atouf F
    J Pharm Sci; 2020 Oct; 109(10):2958-2961. PubMed ID: 32710904
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 2D and 3D inkjet printing of biopharmaceuticals - A review of trends and future perspectives in research and manufacturing.
    Evans SE; Harrington T; Rodriguez Rivero MC; Rognin E; Tuladhar T; Daly R
    Int J Pharm; 2021 Apr; 599():120443. PubMed ID: 33675921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Digitalization and Bioprocessing: Promises and Challenges.
    Scheper T; Beutel S; McGuinness N; Heiden S; Oldiges M; Lammers F; Reardon KF
    Adv Biochem Eng Biotechnol; 2021; 176():57-69. PubMed ID: 32865594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies.
    Demmon S; Bhargava S; Ciolek D; Halley J; Jaya N; Joubert MK; Koepf E; Smith P; Trexler-Schmidt M; Tsai P
    Biologicals; 2020 Sep; 67():9-20. PubMed ID: 32665104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NIIMBL-Facilitated Active Listening Meeting between Industry and FDA Identifies Common Challenges for Adoption of New Biopharmaceutical Manufacturing Technologies.
    Mantle JL; Lee KH
    PDA J Pharm Sci Technol; 2020; 74(5):497-508. PubMed ID: 32467179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Applications of Artificial Intelligence and Machine Learning Algorithms to Crystallization.
    Xiouras C; Cameli F; Quilló GL; Kavousanakis ME; Vlachos DG; Stefanidis GD
    Chem Rev; 2022 Aug; 122(15):13006-13042. PubMed ID: 35759465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review.
    Kolluri S; Lin J; Liu R; Zhang Y; Zhang W
    AAPS J; 2022 Jan; 24(1):19. PubMed ID: 34984579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Towards a Digital Bioprocess Replica: Computational Approaches in Biopharmaceutical Development and Manufacturing.
    Smiatek J; Jung A; Bluhmki E
    Trends Biotechnol; 2020 Oct; 38(10):1141-1153. PubMed ID: 32518043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk-Based Selection of Environmental Classifications for Biopharmaceutical Operations.
    Bevan N; Corbidge T; Estape D; Hovmand Lyster L; Magnus J
    PDA J Pharm Sci Technol; 2021; 75(4):374-390. PubMed ID: 33443138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A review on patient-specific facial and cranial implant design using Artificial Intelligence (AI) techniques.
    Memon AR; Li J; Egger J; Chen X
    Expert Rev Med Devices; 2021 Oct; 18(10):985-994. PubMed ID: 34404280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biopharmaceutical Manufacturing: Historical Perspectives and Future Directions.
    Szkodny AC; Lee KH
    Annu Rev Chem Biomol Eng; 2022 Jun; 13():141-165. PubMed ID: 35300518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A review on the modernization of pharmaceutical development and manufacturing - Trends, perspectives, and the role of mathematical modeling.
    Destro F; Barolo M
    Int J Pharm; 2022 May; 620():121715. PubMed ID: 35367580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence.
    Schuhmacher A; Gatto A; Kuss M; Gassmann O; Hinder M
    Drug Discov Today; 2021 Oct; 26(10):2226-2231. PubMed ID: 33965571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Model predictive control in pharmaceutical continuous manufacturing: A review from a user's perspective.
    Jelsch M; Roggo Y; Kleinebudde P; Krumme M
    Eur J Pharm Biopharm; 2021 Feb; 159():137-142. PubMed ID: 33429008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A practical discussion of risk management for manufacturing of pharmaceutical products.
    Mollah AH; Baseman HS; Long M; Rathore AS
    PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics.
    Koromina M; Pandi MT; Patrinos GP
    OMICS; 2019 Nov; 23(11):539-548. PubMed ID: 31651216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.